Suche
Mein Konto
Roche is investing 40 million euros in the Penzberg laboratory of the future!
Roche is laying the foundation stone for a new laboratory in Penzberg that will use SBX technology to better decipher complex diseases.
Roche is investing 40 million euros in the Penzberg laboratory of the future!
A new chapter in diagnostic technology will soon be opened in Penzberg: Roche today celebrated the laying of the foundation stone for a modern laboratory building, which is part of the far-reaching investment of around 40 million euros. As the South German newspaper reports, the new laboratory will be responsible for the production of reagents for the innovative “sequencing by expansion” (SBX) technology from summer 2026.
The SBX technology is a real driver of innovation and represents a significant advance in the field of next-generation sequencing (NGS). The aim of this technology is to be able to decipher complex diseases such as cancer as well as immune and neurodegenerative diseases, making diagnostics more personalized and faster. District Administrator Andrea Jochner-Weiß also emphasizes this: “This project not only strengthens the Penzberg location, but also the entire Weilheim-Schongau region,” she said.
A new era of diagnostics
Paul Wiggermann, the Roche site manager in Penzberg, emphasizes the central role that the new laboratory will play in the Roche Group. Here, a large number of up to 20 different diagnostic materials are produced in four separate laboratories, with the separation of the laboratories being crucial in order to avoid cross-contamination and to guarantee the highest product quality.
The laboratory building will have a usable area of 833 square meters on the ground floor and 630 square meters for a technology center on the upper floor. The construction relies on sustainable materials, energy-efficient insulation and a photovoltaic system, which corresponds to Roche's company ethos of advancing not only technologically but also ecologically.
Technological progress in one location
The SBX technology that Roche is establishing in Penzberg is a response to the constantly increasing demand for more efficient sequencing methods. According to Roche, this new technology enables ultra-fast, high-throughput sequencing that is flexible and scalable. Marco Cairoli, head of diagnostics production, emphasizes that the expertise of the employees is crucial for the implementation of this advanced technology.
“With this investment we are creating 15 qualified jobs,” adds Cairoli. This not only strengthens the Penzberg location, but also promotes the company's overall competitiveness. The new technologies raise the possibilities of diagnostics to a new level and make Roche a pioneer in genomic research.
Roche recognizes that the future of medicine lies in more precise diagnostics and, with SBX technology, is committed to advances that will not only have an impact worldwide, but also directly in the region. By pooling their resources and using state-of-the-art technology, Penzberg could soon become a center for innovative medical solutions, which is of significant relevance not only to the local economy, but also to the entire industry.